Synthetic cannabinoids are lab-made chemicals designed to interact with the same brain receptors as THC, the psychoactive compound in marijuana. They are not a single drug but a large and constantly shifting family of compounds, sold under street names like K2, Spice, and Mamba. Despite being marketed as safe or “natural” alternatives to cannabis, they are far more unpredictable and dangerous than plant-based marijuana.
How They Were Created
Synthetic cannabinoids were originally developed by pharmaceutical researchers studying the body’s cannabinoid receptor system. The goal was to create compounds that could replicate the therapeutic effects of natural cannabinoids without the psychoactive high. These efforts produced not only molecules that looked structurally similar to THC, but also entirely new chemical structures that happened to activate the same receptors. Starting around 2005, these research chemicals began showing up in “herbal incense” products sold in European smoke shops, then reached the United States by 2008.
Why They Hit Harder Than Marijuana
The effects of synthetic cannabinoids come from their ability to bind to the CB1 receptor in the brain, the same receptor THC targets. The critical difference is how tightly they bind. Some synthetic compounds grip this receptor far more aggressively than THC does. Lab testing shows that certain variants bind to CB1 with roughly 16 times the affinity of THC, while others bind with less. Across the full range of known compounds, potency estimates vary from 2 to 800 times that of THC.
This extreme variation is part of what makes synthetic cannabinoids so dangerous. Two packets of the same brand bought a week apart can contain entirely different chemicals at different concentrations. Users have no way to gauge what they’re actually consuming or how strong it is.
What the Products Look Like
The synthetic chemical itself is typically produced as a powder in overseas labs. To create a smokeable product, manufacturers dissolve the powder in a solvent like acetone, then spray the solution onto dried plant material. The plant base is usually a mix of inexpensive herbs: damiana leaf, marshmallow leaf, mullein, or other botanical scraps chosen for bulk rather than any psychoactive property. Flavorings are sometimes added. The finished product is packaged in small, brightly colored foil pouches and labeled “not for human consumption” to skirt regulations.
Because the chemical is sprayed rather than uniformly mixed, the concentration can vary wildly even within a single packet. One pinch might contain a mild dose while the next delivers a potentially lethal one.
Effects and Symptoms
At lower doses, synthetic cannabinoids can produce effects loosely similar to marijuana: euphoria, talkativeness, and changes in how sounds and visuals are perceived. But the experience is often more intense and less controllable. Users frequently report rapid heart rate, extreme anxiety, agitation, and confusion that goes well beyond anything typical of cannabis.
At higher doses or with more potent compounds, the effects can escalate to seizures, loss of consciousness, psychotic episodes with hallucinations, and violent behavior. Emergency departments have documented waves of mass intoxication events where dozens of people in the same area collapse within hours of each other after using products from the same batch.
Serious Medical Complications
Beyond the immediate psychological effects, synthetic cannabinoids can cause organ damage that natural cannabis does not. Most adverse events reported in clinical settings fall into three categories: neurological, cardiovascular, and those involving an overstimulated “fight or flight” response.
Kidney failure is one of the more alarming complications. In 2012, the CDC documented 16 cases of acute kidney injury across six states in previously healthy young men who had recently smoked synthetic cannabinoid products. These patients developed severe nausea, vomiting, and abdominal pain. Their creatinine levels, a marker of kidney function, spiked to as high as 21 mg/dL, compared to a normal range of 0.6 to 1.3. Five of the 16 patients required dialysis. Biopsies showed direct damage to the kidney tissue itself.
Cardiovascular effects include dangerously elevated heart rate and blood pressure, chest pain, and in rare cases, heart attack. The unpredictable potency of these products means that even experienced users can suddenly encounter a dose their body cannot handle.
They Don’t Show Up on Standard Drug Tests
One reason synthetic cannabinoids remain popular, particularly among people subject to regular drug screening, is that standard urine tests cannot detect them. The typical five-panel drug test screens for THC, cocaine, amphetamines, opioids, and PCP. Synthetic cannabinoids and their breakdown products do not cross-react with the THC portion of these tests.
Specialized lab testing can identify specific synthetic cannabinoid compounds in blood or urine, but these tests are expensive and must be specifically ordered. Even then, the detection window in blood and oral fluid is generally short, though chronic heavy use may extend it somewhat. Because parent compounds are rarely found in urine, confirmatory testing in workplace settings is difficult. This gap in detectability has made synthetic cannabinoids particularly common among people on probation, in the military, or in jobs with routine drug screening.
Legal Status
In the United States, 43 specific synthetic cannabinoid compounds are classified as Schedule I controlled substances, the most restrictive category. Many additional compounds fall under the Controlled Substances Act’s definition of “cannabimimetic agents,” which also places them in Schedule I.
The challenge for regulators is that underground chemists can tweak the molecular structure of a banned compound just enough to create a technically new substance that falls outside existing scheduling. To address this, the DEA uses the Controlled Substance Analogue Enforcement Act, which allows prosecutors to treat any substance “substantially similar” to a Schedule I drug as if it were also Schedule I. The DEA has successfully used this law to prosecute manufacturers and distributors even when the exact compound involved had never been formally scheduled.
Who Is Using Them and Where
Emergency department data collected through SAMHSA’s DAWN surveillance network recorded 3,617 visits involving synthetic cannabinoids between 2020 and early 2025. The rate peaked at 176 per 10,000 DAWN visits in November 2020, then declined until mid-2022. Since then, visits have been climbing again at roughly 3% per month. Geographically, synthetic cannabinoid emergencies are concentrated in the Northeast and in urban areas.
Use tends to cluster among people experiencing homelessness, those in institutional settings where drug testing is common, and younger adults. The low price point, sometimes just a few dollars per dose, and easy availability in gas stations and corner stores (despite enforcement efforts) keep these products accessible to vulnerable populations.